300705 九典制药
已收盘 01-29 15:00:00
资讯
新帖
简况
股市必读：九典制药（300705）1月26日董秘有最新回复
证券之星 · 01-27 02:07
股市必读：九典制药（300705）1月26日董秘有最新回复
九典制药完成工商变更登记 经营范围规范化调整
中金财经 · 01-15
九典制药完成工商变更登记 经营范围规范化调整
九典制药：中信建投、申万宏源等多家机构于1月13日调研我司
证券之星 · 01-14
九典制药：中信建投、申万宏源等多家机构于1月13日调研我司
九典制药（300705）披露2022年限制性股票激励计划第三个归属期第二批次归属结果暨股份上市，1月7日股价下跌0.19%
证券之星 · 01-07
九典制药（300705）披露2022年限制性股票激励计划第三个归属期第二批次归属结果暨股份上市，1月7日股价下跌0.19%
九典制药（300705）披露关于回购公司股份的进展公告，1月5日股价上涨3.4%
证券之星 · 01-05
九典制药（300705）披露关于回购公司股份的进展公告，1月5日股价上涨3.4%
九典制药2025年第四季度可转债转股26张，总股本微增至5亿股
中金财经 · 01-05
九典制药2025年第四季度可转债转股26张，总股本微增至5亿股
每周股票复盘：九典制药（300705）股东会通过章程修订等议案
证券之星 · 01-03
每周股票复盘：九典制药（300705）股东会通过章程修订等议案
九典制药（300705）披露变更经营范围及修订《公司章程》公告，12月31日股价下跌1.06%
证券之星 · 2025-12-31
九典制药（300705）披露变更经营范围及修订《公司章程》公告，12月31日股价下跌1.06%
九典制药（300705）披露召开2025年第二次临时股东会提示性公告，12月26日股价下跌0.71%
证券之星 · 2025-12-26
九典制药（300705）披露召开2025年第二次临时股东会提示性公告，12月26日股价下跌0.71%
九典制药（300705）披露2025年度持续督导定期现场检查报告，12月24日股价上涨0.13%
证券之星 · 2025-12-24
九典制药（300705）披露2025年度持续督导定期现场检查报告，12月24日股价上涨0.13%
九典制药变更可转债募资用途 调整经营布局
中金财经 · 2025-12-23
九典制药变更可转债募资用途 调整经营布局
九典制药：正在全面转型创新药研发，迅速布局创新药
第一财经 · 2025-12-18
九典制药：正在全面转型创新药研发，迅速布局创新药
九典制药（300705）披露撤回药品注册申请公告，12月17日股价上涨0.99%
证券之星 · 2025-12-17
九典制药（300705）披露撤回药品注册申请公告，12月17日股价上涨0.99%
九典制药最新公告：撤回吲哚美辛凝胶贴膏药品注册申请
证券之星 · 2025-12-17
九典制药最新公告：撤回吲哚美辛凝胶贴膏药品注册申请
九典制药拟取消监事会并修订公司章程及多项治理制度
中金财经 · 2025-12-12
九典制药拟取消监事会并修订公司章程及多项治理制度
九典制药最新公告：获得马来酸曲美布汀片药品注册证书
证券之星 · 2025-12-11
九典制药最新公告：获得马来酸曲美布汀片药品注册证书
九典制药（300705）披露获得药物临床试验批准通知书，12月09日股价下跌0.87%
证券之星 · 2025-12-09
九典制药（300705）披露获得药物临床试验批准通知书，12月09日股价下跌0.87%
九典制药(300705.SZ)：JMHT06药物临床试验获批准
智通财经 · 2025-12-09
九典制药(300705.SZ)：JMHT06药物临床试验获批准
九典制药：在研治疗寻常痤疮1.1类创新药JIJ02
证券之星 · 2025-12-09
九典制药：在研治疗寻常痤疮1.1类创新药JIJ02
【私募调研记录】汇智融达调研九典制药
证券之星 · 2025-12-09
【私募调研记录】汇智融达调研九典制药
加载更多
公司概况
公司名称：
湖南九典制药股份有限公司
所属行业：
医药制造业
上市日期：
2017-10-10
主营业务：
湖南九典制药股份有限公司的主营业务是化药制剂、原料药、药用辅料、中药、大健康产品等的研发、生产、销售、CXO服务。公司的主要产品是药品制剂、原料药及药用辅料。公司先后获评安全生产标准化三级企业、安全生产示范企业等称号。
发行价格：
10.37
{"stockData":{"symbol":"300705","market":"SZ","secType":"STK","nameCN":"九典制药","latestPrice":15.56,"timestamp":1769670204000,"preClose":15.61,"halted":0,"volume":5762254,"delay":0,"changeRate":-0.0032,"floatShares":369000000,"shares":500000000,"eps":0.9375,"marketStatus":"已收盘","change":-0.05,"latestTime":"01-29 15:00:00","open":15.55,"high":15.66,"low":15.35,"amount":89288200,"amplitude":0.0199,"askPrice":15.56,"askSize":168,"bidPrice":15.55,"bidSize":31,"shortable":0,"etf":0,"ttmEps":0.9375,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1769736600000},"marketStatusCode":5,"adr":0,"adjPreClose":15.61,"symbolType":"stock","openAndCloseTimeList":[[1769650200000,1769657400000],[1769662800000,1769670000000]],"highLimit":17.17,"lowLimit":14.05,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":500291060,"isCdr":false,"pbRate":2.96,"roa":"--","peRate":16.597333,"roe":"14.85%","epsLYR":1.05,"committee":-0.405874,"marketValue":7785000000,"turnoverRate":0.0156,"status":1,"floatMarketCap":5741000000},"requestUrl":"/m/hq/s/300705","defaultTab":"news","newsList":[{"id":"2606240262","title":"股市必读：九典制药（300705）1月26日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2606240262","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606240262?lang=zh_cn&edition=full","pubTime":"2026-01-27 02:07","pubTimestamp":1769450832,"startTime":"0","endTime":"0","summary":"截至2026年1月26日收盘，九典制药报收于16.08元，上涨0.75%，换手率3.15%，成交量11.63万手，成交额1.86亿元。董秘最新回复投资者： 目前公司的股东人数是多少？公司股东人数按规定在定期报告中进行披露，请参见公司定期报告。感谢您对公司的关注！交易信息汇总资金流向1月26日主力资金净流出877.38万元；游资资金净流入1970.67万元；散户资金净流出1093.29万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012700001708.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2603072856","title":"九典制药完成工商变更登记 经营范围规范化调整","url":"https://stock-news.laohu8.com/highlight/detail?id=2603072856","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603072856?lang=zh_cn&edition=full","pubTime":"2026-01-15 20:43","pubTimestamp":1768480984,"startTime":"0","endTime":"0","summary":"中访网数据 湖南九典制药股份有限公司于近日完成了工商变更登记手续，并取得了由长沙市市场监督管理局换发的新版《营业执照》。本次变更主要涉及公司经营范围的调整，系根据市场监督管理部门关于经营范围登记规范化的要求，通过规范表述查询系统选取匹配条目后进行的标准化更新。公司强调，此次调整仅为文字表述的规范化，未涉及公司实质经营内容的变动。此次工商变更源于公司2025年第二次临时股东会审议通过的《关于变更经营范围及修订的议案》，相关决议已于此前进行披露。同时，公司已依据核准后的经营范围完成了《公司章程》的修订及备案登记。本次变更标志着九典制药的公司治理及登记信息进一步符合监管规范。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260115/31945964.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2603654195","title":"九典制药：中信建投、申万宏源等多家机构于1月13日调研我司","url":"https://stock-news.laohu8.com/highlight/detail?id=2603654195","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2603654195?lang=zh_cn&edition=full","pubTime":"2026-01-14 09:08","pubTimestamp":1768352932,"startTime":"0","endTime":"0","summary":"证券之星消息，2026年1月13日九典制药发布公告称中信建投、申万宏源、言是科技、彼得明奇于2026年1月13日调研我司。首先，在院内市场，公司将着力确保洛索洛芬钠凝胶贴膏在集采执行后的院内销量基础，同时重点推广酮洛芬凝胶贴膏及新收购的独家品种代温灸膏等品种。该股最近90天内共有2家机构给出评级，买入评级2家。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011400007032.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0028","BK0188","300705","000166","BK1147","06806","601066","BK0183","BK0276","BK1564","BK0239","BK0012"],"gpt_icon":0},{"id":"2601801273","title":"九典制药（300705）披露2022年限制性股票激励计划第三个归属期第二批次归属结果暨股份上市，1月7日股价下跌0.19%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601801273","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601801273?lang=zh_cn&edition=full","pubTime":"2026-01-07 22:42","pubTimestamp":1767796936,"startTime":"0","endTime":"0","summary":"截至2026年1月7日收盘，九典制药报收于15.51元，较前一交易日下跌0.19%，最新总市值为77.58亿元。公司近日发布公告，披露关于2022年限制性股票激励计划第三个归属期第二批次归属结果暨股份上市的进展情况。公告显示，本次归属股票上市流通日为2026年1月9日，涉及人数1人，归属股票数量7.84万股，占公司总股本的0.016%。公司层面业绩考核达标，归属比例为100%。本次归属已完成股份登记，募集资金用于补充流动资金。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010700039218.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2601688735","title":"九典制药（300705）披露关于回购公司股份的进展公告，1月5日股价上涨3.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2601688735","media":"证券之星","labels":["shareholding","buyback"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601688735?lang=zh_cn&edition=full","pubTime":"2026-01-05 22:23","pubTimestamp":1767622998,"startTime":"0","endTime":"0","summary":"截至2026年1月5日收盘，九典制药报收于15.49元，较前一交易日上涨3.4%，最新总市值为77.48亿元。该股当日开盘15.06元，最高15.53元，最低15.0元，成交额达1.59亿元，换手率为2.82%。公司近日发布公告，就回购公司股份的进展情况作出说明。湖南九典制药股份有限公司于2025年2月17日召开董事会，审议通过回购股份方案，拟通过集中竞价交易方式以自有资金及专项贷款回购股份，用于股权激励。回购进展符合相关规定。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010500040110.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding,buyback","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2601431002","title":"九典制药2025年第四季度可转债转股26张，总股本微增至5亿股","url":"https://stock-news.laohu8.com/highlight/detail?id=2601431002","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601431002?lang=zh_cn&edition=full","pubTime":"2026-01-05 17:25","pubTimestamp":1767605104,"startTime":"0","endTime":"0","summary":"中访网数据 湖南九典制药股份有限公司于2026年1月5日披露了2025年第四季度可转换公司债券转股情况。公告显示，在2025年第四季度，公司发行的“九典转02”共有26张完成转股，对应债券票面金额2，600元，转换为公司股票172股，转股价格为14.95元/股。截至2025年12月31日，“九典转02”尚未转股部分剩余2，052，772张，剩余票面总金额约为2.05亿元。本次转股导致公司总股本发生微小变动，由500，212，488股增加至500，212，660股。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20260105/31915320.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2600067215","title":"每周股票复盘：九典制药（300705）股东会通过章程修订等议案","url":"https://stock-news.laohu8.com/highlight/detail?id=2600067215","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2600067215?lang=zh_cn&edition=full","pubTime":"2026-01-03 03:00","pubTimestamp":1767380435,"startTime":"0","endTime":"0","summary":"本周关注点公司公告汇总：九典制药2025年第二次临时股东会审议通过变更经营范围及修订《公司章程》等议案。公司公告汇总湖南九典制药股份有限公司于2025年12月30日召开2025年第二次临时股东会，会议由董事会召集，采取现场与网络投票相结合方式举行。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010300000782.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2595720446","title":"九典制药（300705）披露变更经营范围及修订《公司章程》公告，12月31日股价下跌1.06%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595720446","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595720446?lang=zh_cn&edition=full","pubTime":"2025-12-31 17:43","pubTimestamp":1767174180,"startTime":"0","endTime":"0","summary":"截至2025年12月31日收盘，九典制药报收于14.98元，较前一交易日下跌1.06%，最新总市值为74.93亿元。该股当日开盘15.14元，最高15.14元，最低14.98元，成交额达7093.21万元，换手率为1.28%。近日，九典制药发布2025年第二次临时股东会决议公告，公司于2025年12月30日召开2025年第二次临时股东会，审议通过《关于变更经营范围及修订<公司章程>的议案》和《关于制定及修订部分治理制度的议案》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123100032485.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2594129411","title":"九典制药（300705）披露召开2025年第二次临时股东会提示性公告，12月26日股价下跌0.71%","url":"https://stock-news.laohu8.com/highlight/detail?id=2594129411","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594129411?lang=zh_cn&edition=full","pubTime":"2025-12-26 22:34","pubTimestamp":1766759657,"startTime":"0","endTime":"0","summary":"截至2025年12月26日收盘，九典制药报收于15.28元，较前一交易日下跌0.71%，最新总市值为76.43亿元。该股当日开盘15.39元，最高15.39元，最低15.24元，成交额达7043.14万元，换手率为1.24%。公司近日发布公告，将于2025年12月30日召开2025年第二次临时股东会，会议由董事会召集，现场会议时间为当日14:30，网络投票时间为同日9:15至15:00。股权登记日为2025年12月19日。中小投资者表决结果将单独计票并披露。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122600036623.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2593475930","title":"九典制药（300705）披露2025年度持续督导定期现场检查报告，12月24日股价上涨0.13%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593475930","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593475930?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:52","pubTimestamp":1766569922,"startTime":"0","endTime":"0","summary":"截至2025年12月24日收盘，九典制药报收于15.38元，较前一交易日上涨0.13%，最新总市值为76.93亿元。该股当日开盘15.36元，最高15.4元，最低15.28元，成交额达5870.67万元，换手率为1.03%。近日，西部证券股份有限公司发布关于九典制药2025年度持续督导定期现场检查报告。公告显示，西部证券作为保荐机构，对湖南九典制药股份有限公司2025年度持续督导进行了现场检查，检查期间为2025年度，检查时间为2025年12月15日和19日。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122400029106.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2593494305","title":"九典制药变更可转债募资用途 调整经营布局","url":"https://stock-news.laohu8.com/highlight/detail?id=2593494305","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593494305?lang=zh_cn&edition=full","pubTime":"2025-12-23 19:05","pubTimestamp":1766487941,"startTime":"0","endTime":"0","summary":"中访网数据 湖南九典制药股份有限公司于2025年8月21日召开第四届董事会第十二次会议及第四届监事会第八次会议，审议通过了《关于改变募集资金用途的议案》。公司决定改变其向不特定对象发行可转换公司债券所募集资金的用途。此次变更主要基于公司对当前政策与市场环境变化的研判，以及对整体经营布局的战略性调整。根据公告，本次募集资金用途的变更已履行了必要的内部审议程序。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251223/31885531.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2592902107","title":"九典制药：正在全面转型创新药研发，迅速布局创新药","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902107","media":"第一财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592902107?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:13","pubTimestamp":1766067180,"startTime":"0","endTime":"0","summary":"九典制药在机构调研时表示，公司目前正在全面转型创新药研发，采用“多个研发中心+多种药物形式+多种合作模式”策略迅速布局创新药。(本文来自第一财经)\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfvmf2970774.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2025-12-18/doc-inhcfvmf2970774.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["159992","BK1574","06978","BK1161","300705","BK0239"],"gpt_icon":0},{"id":"2592164915","title":"九典制药（300705）披露撤回药品注册申请公告，12月17日股价上涨0.99%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592164915","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592164915?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:19","pubTimestamp":1765981159,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，九典制药报收于15.35元，较前一交易日上涨0.99%，最新总市值为76.78亿元。该股当日开盘15.2元，最高15.38元，最低15.17元，成交额达6056.42万元，换手率为1.07%。公司于近日发布公告称，湖南九典制药股份有限公司收到国家药品监督管理局核准签发的《药品注册申请终止通知书》，同意撤回吲哚美辛凝胶贴膏药品注册申请。该药品属于化学药品3类，用于骨关节炎、肩周炎等疾病的消炎镇痛。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700039610.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2592092996","title":"九典制药最新公告：撤回吲哚美辛凝胶贴膏药品注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2592092996","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592092996?lang=zh_cn&edition=full","pubTime":"2025-12-17 18:21","pubTimestamp":1765966879,"startTime":"0","endTime":"0","summary":"九典制药公告称，公司收到国家药品监督管理局核准签发的《药品注册申请终止通知书》，同意公司撤回吲哚美辛凝胶贴膏药品注册申请。该药品于2020年2月获得临床试验批准，2023年11月完成Ⅲ期临床试验并取得总结报告，12月提交上市许可申请并获得受理。因需进一步完善相关试验数据，公司决定撤回注册申请，后续将补充完善相关研究后重新启动申报注册程序。但药品研发具有不确定性，存在研发进程不及预期、未能获得上市批准的风险。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700029566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2590146540","title":"九典制药拟取消监事会并修订公司章程及多项治理制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2590146540","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590146540?lang=zh_cn&edition=full","pubTime":"2025-12-12 08:14","pubTimestamp":1765498472,"startTime":"0","endTime":"0","summary":"中访网数据 湖南九典制药股份有限公司于2025年12月11日召开第四届董事会第十六次会议，审议通过了关于取消监事会及修订《公司章程》等一系列公司治理制度的议案。本次《公司章程》修订及部分治理制度的制定修订尚需提交公司股东大会审议批准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251212/31860714.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2590516736","title":"九典制药最新公告：获得马来酸曲美布汀片药品注册证书","url":"https://stock-news.laohu8.com/highlight/detail?id=2590516736","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590516736?lang=zh_cn&edition=full","pubTime":"2025-12-11 21:20","pubTimestamp":1765459212,"startTime":"0","endTime":"0","summary":"九典制药(300705.SZ)公告称，公司近日收到国家药品监督管理局下发的马来酸曲美布汀片药品注册证书。该药品用于治疗肠易激综合征和胃肠道运动功能紊乱引起的症状，国内共有6家企业取得该证书，公司为国内第5家通过或视同通过仿制药质量和疗效一致性评价的企业。该证书的取得丰富了公司的产品管线，对进一步优化公司产品结构有积极意义。但需注意药品生产和销售受多种因素影响，存在不确定性。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121100039600.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300705"],"gpt_icon":0},{"id":"2590428863","title":"九典制药（300705）披露获得药物临床试验批准通知书，12月09日股价下跌0.87%","url":"https://stock-news.laohu8.com/highlight/detail?id=2590428863","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590428863?lang=zh_cn&edition=full","pubTime":"2025-12-09 22:14","pubTimestamp":1765289694,"startTime":"0","endTime":"0","summary":"截至2025年12月9日收盘，九典制药报收于15.93元，较前一交易日下跌0.87%，最新总市值为79.68亿元。该股当日开盘16.08元，最高16.12元，最低15.91元，成交额达7164.81万元，换手率为1.21%。公司近日发布公告称，湖南九典制药股份有限公司收到国家药品监督管理局签发的《药物临床试验批准通知书》，同意其化药2.2类外用制剂JMHT06开展痛风性关节炎急性发作适应症的临床试验。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900040544.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2590489316","title":"九典制药(300705.SZ)：JMHT06药物临床试验获批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2590489316","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590489316?lang=zh_cn&edition=full","pubTime":"2025-12-09 16:36","pubTimestamp":1765269378,"startTime":"0","endTime":"0","summary":"智通财经APP讯，九典制药(300705.SZ)公告，公司近日收到国家药品监督管理局签发的《药物临床试验批准通知书》，在完成相关准备工作后，JMHT06将开展痛风性关节炎急性发作适应症临床试验。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379308.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"九典制药(300705.SZ)：JMHT06药物临床试验获批准","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["300705","BK0239"],"gpt_icon":0},{"id":"2590993963","title":"九典制药：在研治疗寻常痤疮1.1类创新药JIJ02","url":"https://stock-news.laohu8.com/highlight/detail?id=2590993963","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590993963?lang=zh_cn&edition=full","pubTime":"2025-12-09 11:37","pubTimestamp":1765251438,"startTime":"0","endTime":"0","summary":"证券之星消息，九典制药12月09日在投资者关系平台上答复投资者关心的问题。贵司有没有治疗痤疮青春痘之类的洗护用常规药或者特效药？对于公司来说，这也是一块持续的源源不断的市场！公司目前在研的有用于治疗寻常痤疮的1.1类创新药JIJ02，该项目正处于临床I期阶段。JIJ02是一种结构明确、具有药理作用的新化合物，其凝胶制剂可用于治疗寻常痤疮。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025120900013640.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159992","BK1574","06978","BK1161","BK0239","300705"],"gpt_icon":0},{"id":"2590136255","title":"【私募调研记录】汇智融达调研九典制药","url":"https://stock-news.laohu8.com/highlight/detail?id=2590136255","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590136255?lang=zh_cn&edition=full","pubTime":"2025-12-09 08:04","pubTimestamp":1765238692,"startTime":"0","endTime":"0","summary":"根据市场公开信息及12月8日披露的机构调研信息，知名私募汇智融达近期对1家上市公司进行了调研，相关名单如下：1）九典制药 调研纪要：公司通过拓展院外市场、强化“贴膏药，换九典”品牌建设、加大研发与并购力度应对集采影响。机构简介：深圳汇智融达基金管理有限公司，中国私募基金管理人，成立于2015年 8月，经深圳市场监督管理局批准成立，注册资本1千万元，是一家以私募基金管理，资产配置的专业金融机构。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://fund.stockstar.com/RB2025120900004082.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300705","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1769697800764,"stockEarnings":[{"period":"1week","weight":-0.0057},{"period":"1month","weight":0.0351},{"period":"3month","weight":-0.0412},{"period":"6month","weight":-0.1688},{"period":"1year","weight":0.0252},{"period":"ytd","weight":0.0421}],"compareEarnings":[{"period":"1week","weight":0.0083},{"period":"1month","weight":0.0469},{"period":"3month","weight":0.0412},{"period":"6month","weight":0.1661},{"period":"1year","weight":0.2771},{"period":"ytd","weight":0.046}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"湖南九典制药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"34736人(较上一季度减少10.37%)","perCapita":"10621股","listingDate":"2017-10-10","address":"湖南省长沙市浏阳市经济技术开发区健康大道1号","registeredCapital":"50029万元","survey":" 湖南九典制药股份有限公司的主营业务是化药制剂、原料药、药用辅料、中药、大健康产品等的研发、生产、销售、CXO服务。公司的主要产品是药品制剂、原料药及药用辅料。公司先后获评安全生产标准化三级企业、安全生产示范企业等称号。","listedPrice":10.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"九典制药,300705,九典制药股票,九典制药股票老虎,九典制药股票老虎国际,九典制药行情,九典制药股票行情,九典制药股价,九典制药股市,九典制药股票价格,九典制药股票交易,九典制药股票购买,九典制药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"九典制药(300705)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供九典制药(300705)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}